Abstracts Archive - Page 1864 of 2607 - ACR Meeting Abstracts

Abstract Number: 3155 • 2015 ACR/ARHP Annual Meeting
Bob1 Expression Is Elevated in Rheumatoid Synovium and Its Expression in B Cells Is Required for Development of Collagen-Induced Arthritis
Maartje Levels^1,2,3, Melissa van Tok^2,3,4, Tineke Cantaert^2,3, Frans G.M. Kroese⁵, Hergen Spits⁶, Dominique Baeten^2,3,4 and Nataliya Yeremenko^1,2,3, ¹Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, ²Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Laboratory of Experimental Immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁴Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁵Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁶Department of Cell Biology and Histology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a prototypic autoimmune disease characterized by a prominent humoral autoimmunity. Of particular relevance is the local production of autoantibodies and…
Abstract Number: 3156 • 2015 ACR/ARHP Annual Meeting
IL17 Promotes Development of Autoreactive Early Stage B Cells in Distinct Regions of the Spleen Follicle
Jennie Hamilton¹, Qi Wu², PingAr Yang³, Jun Li⁴, Yanna Ding¹, Bao Luo⁵, John Mountz⁶ and Hui-Chen Hsu², ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁶Dept of Med/Rheumatology Div, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The early stage transitional B cell has been shown to be the key peripheral B-cell tolerance control point defect in SLE patients. Anti-RNP Abs can…
Abstract Number: 3157 • 2015 ACR/ARHP Annual Meeting
B Cell Profile As a Biomarker of Disease Segmentation and Flare Prognosis in SLE
Chungwen Wei¹, Bridget Neary², Jamie Biear³, Jennifer Barnard^3,4, Michelle Petri⁵, Alex Rosenberg⁶, Jennifer H. Anolik⁷ and Ignacio Sanz¹, ¹Rheumatology, Emory University, Atlanta, GA, ²Emory University, Atlanta, GA, ³Rheumatology, University of Rochester, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁵Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ⁶University of Rochester, Rochester, NY, ⁷University of Rochester Medical Center, Rochester, NY
Background/Purpose: B cell abnormalities in SLE are well-established contributors to disease pathogenesis. Perturbation of B cell homeostasis in SLE is often described separately for each…
Abstract Number: 3158 • 2015 ACR/ARHP Annual Meeting
Impact of Family History of Systemic Lupus Erythematosus on Risk of Autoimmune Diseases: National Cohort Study in Denmark 1977-2012
Constance Jensina Ulff-Møller¹, Jacob Simonsen², Søren Jacobsen¹ and Morten Frisch², ¹Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ²Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease (AID), which develops through the interplay of genetic, epigenetic and environmental factors and may cluster…
Abstract Number: 3159 • 2015 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Is a Risk Factor for Young Stroke: A Population-Based Cohort Study
Elizabeth V Arkema¹, Elisabet Svenungsson², Christopher Sjöwall³ and Julia F Simard^4,5, ¹Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ²Department of Medicine, Karolinska Insitutet, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, ³Department of Clinical and Experimental Medicine, Rheumatology/AIR, Linköping, Sweden, ⁴Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, ⁵Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Previous studies indicate that individuals with SLE have a high risk of stroke but have not investigated when the highest risk occurs. We aimed…
Abstract Number: 3160 • 2015 ACR/ARHP Annual Meeting
Comparative Rates of Serious Infections and All-Cause Mortality Among Systemic Lupus Erythematosus Patients Receiving Mycophenolate Mofetil Versus Azathioprine
Candace H. Feldman¹, Francisco M. Marty², Wolfgang C. Winkelmayer³, Hongshu Guan⁴, Jessica M. Franklin⁵, Daniel H. Solomon¹, Seoyoung C. Kim⁶ and Karen H. Costenbader⁷, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Department of Medicine, Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, ³Medicine-Nephrology, Baylor College of Medicine, Houston, TX, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁶Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at high risk of infections partly from use of immunosuppressives (IS). Clinical trials are powered to detect…
Abstract Number: 3161 • 2015 ACR/ARHP Annual Meeting
Rates of Hospitalization for Infection and Related Mortality By Race/Ethnicity and Sex Among Patients with End-Stage Renal Disease Due to Systemic Lupus Erythematosus
Candace H. Feldman¹, Francisco M. Marty², Wolfgang C. Winkelmayer³, Hongshu Guan⁴, Jessica M. Franklin⁵, Seoyoung C. Kim⁶, Daniel H. Solomon⁷ and Karen H. Costenbader^8,9, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Department of Medicine, Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, ³Medicine-Nephrology, Baylor College of Medicine, Houston, TX, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁶Medicine, Division of Rheumatology, Division of Pharmacoepidemiology, Brigham & Women's Hospital, Boston, MA, ⁷Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁸Rheumatology, Brigham & Women's Hospital, Boston, MA, ⁹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Infections are a significant cause of morbidity and mortality in SLE patients. Recent studies show that lupus nephritis patients have more than two-fold higher…
Abstract Number: 3162 • 2015 ACR/ARHP Annual Meeting
Prevalence of Chronic Comorbidities in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Systemic Lupus Erythematosus: An Analysis of UK Biobank Data
Eftychia Bellou¹, Michael Cook², John Bowes¹, Jamie C Sergeant³, Anne Barton⁴, Terence W. O'Neill² and Suzanne M.M. Verstappen², ¹Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Centre for Musculoskeletal Research, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Centre for Musculoskeletal Research, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ⁴The Kellgren Centre for Rheumatology, Central Manchester Foundation Trust, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and systemic lupus erythematosus (SLE) are immune-mediated disorders and are associated with a number of…
Abstract Number: 3163 • 2015 ACR/ARHP Annual Meeting
The Smoking Paradox in the Development of Psoriatic Arthritis Among Psoriasis Patients
Uyen Sa D.T. Nguyen¹, Yuqing Zhang², Na Lu³, Qiong Louie-Gao⁴, Jingbo Niu⁵, David T. Felson⁵, Michael P. Lavalley⁶, Thorvardur Love^7,8, Maureen Dubreuil⁴, Jeffrey A. Sparks⁹, Elizabeth W. Karlson¹⁰ and Hyon K. Choi³, ¹Orthopedics & Physical Rehabilation, Univerity of Massachusetts Medical School, Worcester, MA, ²Clinical Epidemilogy and Training Unit, Boston University School of Medicine, Boston, MA, ³Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Boston University School of Medicine, Boston, MA, ⁵Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ⁶Biostatistics, Boston University, Boston, MA, ⁷Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁸Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁹Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, ¹⁰Rheumatology, Brigham & Women's Hospital, Boston, MA
Background/Purpose: Smoking is a strong risk factor of psoriasis, but a previous study has suggested that smoking protects against the development of psoriatic arthritis (PsA)…
Abstract Number: 3164 • 2015 ACR/ARHP Annual Meeting
Calcium Pyrophosphate Deposition Disease and Associated Medical Co-Morbidities in the Veteran Population
Crystal Kleiber Balderrama¹, Daniel S. Lans², Ann K. Rosenthal^1,3 and Christie M. Bartels⁴, ¹Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ²Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI, ³Division of Rheumatology, Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI, ⁴Medicine, Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI
Title: Calcium Pyrophosphate Deposition Disease and Associated Medical Co-Morbidities in the Veteran Population. Background/Purpose: Precipitation of calcium pyrophosphate dihydrate (CPP) crystals in articular tissues…
Abstract Number: 3165 • 2015 ACR/ARHP Annual Meeting
Do Omega-3 Fatty Acids Reduce Risk of Recurrent Gout Attacks?
MaryAnn Zhang¹, Yuqing Zhang², Robert Terkeltaub³, Clara Chen⁴ and Tuhina Neogi², ¹Internal Medicine, Boston University School of Medicine, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ⁴Boston University School of Public Health, Boston, MA
Background/Purpose: Current guidelines for gout management, based in part on epidemiologic data for development of incident gout, recommend limiting intake of high-purine fish. However,…
Abstract Number: 3166 • 2015 ACR/ARHP Annual Meeting
Epistatic Interaction of Functional Inflammasome Genetic Variants in Determining the Risk of Gout
Tony R. Merriman¹, Lisa K. Stamp², Nicola Dalbeth³, Ruth Topless⁴, Richard Day⁵, Diluk Kannangara⁵, Kenneth Williams⁵, Matthijs Janssen⁶, Tim Jansen⁷, Leo A. Joosten⁸, Timothy Radstake⁹, Philip L. Riches¹⁰, Anne-Kathrin Tausche¹¹, Frederic Lioté¹², Alex So^13,14 and Cushla McKinney⁴, ¹Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ²Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ³Department of Medicine, University of Auckland, Auckland, New Zealand, ⁴University of Otago, Dunedin, New Zealand, ⁵University of New South Wales, Sydney, Australia, ⁶Rheumatology Dept, Ziekenhuis Rijnstate, Arnhem, Netherlands, ⁷P O Box 581, Haarlem, Netherlands, ⁸Department of Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁹Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁰Centre for Genomic and Experimental Medicine, Western General Hospital, Edinburgh, United Kingdom, ¹¹Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, ¹²Rheumatology Department; Inserm UMR-S606; Paris-Diderot University, hôpital Lariboisiere, Paris, France, ¹³Service De Rhumatologie, CHUV, Lausanne, Switzerland, ¹⁴Department of Rheumatology, CHUV, Lausanne, Switzerland
Background/Purpose: The acute gout flare results from a localised self-limiting innate immune response to monosodium urate (MSU) crystals deposited in joints in hyperuricaemic individuals. Activation…
Abstract Number: 3167 • 2015 ACR/ARHP Annual Meeting
Association of the Apolipoprotein A1-C3-A4 Gene Cluster with the Risk of Gout: Evidence for a Causal Role in Gout
Tony R. Merriman¹, Amanda Phipps-Green², Ruth Topless², Malcolm D. Smith³, Catherine Hill⁴, Susan Lester⁴, Maureen Rischmueller⁵, Matthijs Janssen⁶, Tim Jansen⁷, Leo A. Joosten⁸, Timothy Radstake⁹, Philip L. Riches¹⁰, Anne-Kathrin Tausche¹¹, Frederic Lioté¹², Alex So^13,14, Andre M. van Rij², Gregory T. Jones¹⁵, Sally McCormick¹⁶, Andrew Harrison², Lisa K. Stamp¹⁷, Nicola Dalbeth¹⁸ and Humaira Rasheed¹⁶, ¹Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³Rheumatology, Repatriation General Hospital, Adelaide, Australia, ⁴Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia, ⁵Rheumatology, Queen Elizabeth Hospital, Adelaide, Australia, ⁶Rheumatology Dept, Ziekenhuis Rijnstate, Arnhem, Netherlands, ⁷P O Box 581, Haarlem, Netherlands, ⁸Department of Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁹Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁰Centre for Genomic and Experimental Medicine, Western General Hospital, Edinburgh, United Kingdom, ¹¹Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, ¹²Rheumatology Department; Inserm UMR-S606; Paris-Diderot University, hôpital Lariboisiere, Paris, France, ¹³Service De Rhumatologie, CHUV, Lausanne, Switzerland, ¹⁴Department of Rheumatology, CHUV, Lausanne, Switzerland, ¹⁵Surgery, University of Otago, Dunedin, New Zealand, ¹⁶Department of Biochemistry, University of Otago, Dunedin, New Zealand, ¹⁷Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ¹⁸Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Gout is caused by an inflammatory response to monosodium urate (MSU) crystals and is associated with elevated triglyceride and very low density lipoprotein levels.…
Abstract Number: 3168 • 2015 ACR/ARHP Annual Meeting
How Strong Cardiovascular Risk Factor Are Gouty Tophi?
Rada Gancheva¹, Atanas Kundurdjiev², Mariana Ivanova¹, Todor Kundurzhiev³ and Zlatimir Kolarov⁴, ¹University Hospital "St. Iv. Rilski", Clinic of Rheumatology, Sofia, Bulgaria, ²University Hospital "Alexandrovska", Clinic of Nephrology, Sofia, Bulgaria, ³Medical University, Faculty of Public Health, Sofia, Bulgaria, ⁴Clinic of Rheumatology, University Hospital "St. Iv. Rilski", Clinic of Rheumatology, Sofia, Bulgaria
Background/Purpose: We have not found a study determining cardiovascular (CV) risk in the different stages of gout. This led us to use a complex multimodal…
Abstract Number: 3169 • 2015 ACR/ARHP Annual Meeting
Diagnostic Value of Ultrasound for the Diagnosis of Gout in a Prospective Cross-Sectional Study
Alexis Ogdie-Beatty¹, William J. Taylor², Tuhina Neogi³, Jaap Fransen⁴, Tim Jansen⁵, H. Ralph Schumacher Jr.⁶ and Nicola Dalbeth⁷, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Department of Medicine, University of Otago Wellington, Wellington, New Zealand, ³Clinical Epidemiology, BUSM, Boston, MA, ⁴Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ⁵P O Box 581, Haarlem, Netherlands, ⁶Medicine, Rheumatology, U Penn & VA Med Ctr, Philadelphia, PA, ⁷Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Musculoskeletal ultrasound (US) is a non-invasive option for diagnosing gout. However, little is known about the test characteristics of US for the diagnosis of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].